Control Bionics Ltd. (AU:CBL)
ASX:CBL
Want to see AU:CBL full AI Analyst Report?
Top Page
Control Bionics Ltd.
(Sydney:CBL)
Select Model
Select Model
Rating:49Neutral
Price Target:
AU$0.08
▲(36.67% Upside)
Action:Reiterated
Date:06/11/26
The score is held down primarily by weak financial quality—ongoing losses and negative/declining cash flow despite revenue growth. Technicals are supportive with price strength above moving averages, but momentum indicators are extremely stretched, adding pullback risk. Valuation is also constrained by negative earnings and no dividend yield data.
Positive Factors
Revenue Growth
Sustained double-digit revenue growth demonstrates durable end-market demand for the company’s products. Over 2–6 months this supports scaling of operations and gives management runway to improve unit economics and invest in commercialization to drive longer-term profitability.
Negative Factors
Negative Operating Cash Flow
Persistent negative operating cash flow weakens liquidity and forces dependence on external financing. Over several months this can constrain R&D, commercialization, and customer support initiatives, and increase dilution or refinancing risk if cash conversion does not improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained double-digit revenue growth demonstrates durable end-market demand for the company’s products. Over 2–6 months this supports scaling of operations and gives management runway to improve unit economics and invest in commercialization to drive longer-term profitability.
Read all positive factors
Control Bionics Ltd. (CBL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$37.08M
Dividend YieldN/A
Average Volume (3M)173.99K
Price to Earnings (P/E)―
Beta (1Y)-0.05
Revenue Growth14.88%
EPS Growth35.94%
CountryAU
Employees25
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.02
Shares Outstanding411,961,880
10 Day Avg. Volume327,267
30 Day Avg. Volume173,987
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.44
Price to Sales (P/S)1.29
P/FCF Ratio-1.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Control Bionics Ltd. Business Overview & Revenue Model
Company Description
Operating in Australia and North America, Control Bionics Limited and its subsidiaries specialize in the innovation, development, and market introduction of sophisticated assistive communication technologies. The company's offerings include the Ne...
How the Company Makes Money
null...
Control Bionics Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.07M | 6.14M | 5.35M | 5.64M | 4.50M | 4.09M |
| Gross Profit | 326.42K | 4.11M | 3.90M | 3.71M | -2.91M | 2.50M |
| EBITDA | -5.50M | -5.14M | -5.01M | -5.14M | -5.92M | -3.40M |
| Net Income | -6.50M | -6.11M | -5.91M | -5.63M | -6.11M | -3.55M |
Balance Sheet | ||||||
| Total Assets | 9.93M | 8.23M | 9.03M | 8.70M | 13.44M | 18.35M |
| Cash, Cash Equivalents and Short-Term Investments | 3.06M | 672.66K | 980.76K | 935.50K | 5.21M | 12.33M |
| Total Debt | 258.10K | 435.40K | 961.74K | 128.50K | 284.82K | 14.87K |
| Total Liabilities | 2.20M | 2.72M | 2.76M | 1.58M | 1.51M | 1.19M |
| Stockholders Equity | 7.73M | 5.51M | 6.27M | 7.15M | 11.92M | 17.16M |
Cash Flow | ||||||
| Free Cash Flow | -4.46M | -4.57M | -5.38M | -4.98M | -5.75M | -4.04M |
| Operating Cash Flow | -4.13M | -4.27M | -4.91M | -4.53M | -5.60M | -3.99M |
| Investing Cash Flow | -704.37K | -744.78K | -473.09K | -457.54K | -147.74K | -53.40K |
| Financing Cash Flow | 6.93M | 4.63M | 5.43M | 706.43K | -87.33K | 14.92M |
Control Bionics Ltd. Technical Analysis
Positive
0.06
Price Trends
0.06
Positive
0.06
Positive
0.06
Positive
Market Momentum
<0.01
Negative
92.46
Negative
95.11
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CBL, the sentiment is Positive. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.06, and above the 200-day MA of 0.06, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 92.46 is Negative, neither overbought nor oversold. The STOCH value of 95.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CBL.
Control Bionics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$37.08M | -4.59 | -98.14% | ― | 14.88% | 35.94% | |
44 Neutral | AU$43.98M | -10.47 | -417.72% | ― | -19.47% | 62.28% | |
43 Neutral | AU$3.12M | -0.71 | -358.43% | ― | -52.22% | 44.79% | |
41 Neutral | AU$14.44M | -3.23 | -58.40% | ― | -7.00% | 44.55% | |
41 Neutral | AU$10.75M | -0.37 | 459.94% | ― | 15.99% | 32.67% |
* Healthcare Sector Average
AU:CBL
Control Bionics Ltd.
0.09
0.06
210.34%
AU:UCM
Uscom Limited
0.01
>-0.01
-40.00%
AU:HMD
HeraMED Ltd.
0.04
0.03
245.45%
AU:AT1
Atomo Diagnostics Ltd.
0.02
>-0.01
-20.00%
AU:ADR
Adherium Ltd.
―
―
―
Control Bionics Ltd. Corporate Events
Control Bionics Issues Cautionary Notice on Neurotechnology Presentation
May 4, 2026
Control Bionics has released a presentation outlining general information about its business and neurotechnology offerings, while stressing that the material is high-level and not tailored to any specific commercial or financial circumstances. The...
Control Bionics Secures First U.S. LOI for iOS Speech Device Program
Mar 25, 2026
Control Bionics has signed its first U.S. Letter of Intent for an iOS-based speech generating device program, stemming from its recent partnership with NextLevel. The non-binding agreement with a U.S. customer signals planned annual purchases of d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.